Chronic Myeloid Leukemia

Rüdiger Hehlmann is a Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg, Germany. Founder and Chair, European LeukemiaNet (ELN)Founder and chair of the German CML Study Group 1982-2017Former Secretary GeneralInternational Association of Comparative Research on Leukemia & Related Diseases (IACRLRD)Former Chief of Medicine, Dean & PresidentGerman Society of Hematology and OncologyHonorary member of the Polish and German Societies for Hematology and OncologyCurrent focus: promotion of cooperative research for curing leukemia

• Cytogenetics of Chronic Myeloid Leukemia (CML).- The Biology and Pathogenesis of Chronic Myeloid Leukaemia.- Epidemiology of Chronic Myeloid Leukemia.-Imatinib and the first line CML Therapy.- CML Therapy: A Focus on Second and Third Generation Tyrosine Kinase Inhibitors.- Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.- Pharmacoeconomic considerations for tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.- Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update.- Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death.- A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia.- The Role of Hematopoietic Stem Cell Transplantation in CML.- CML end-phase and blast crisis: implications and management.- The Interferon-alpha Revival in CML.- Managing Pregnancy in Chronic Myeloid Leukemia.- Response-Related Predictors of Survival and of Treatment Free Remission in CML.- Discontinuation or cessation of tyrosine kinase inhibitor treatment in Chronic myeloid leukemia patients with deep molecular response.